middle.news
BCAL Boosts Stake in Genetic Signatures to 18.46% to Expand Diagnostic Horizons
8:57am on Wednesday 26th of August, 2026 AEST
•
Healthcare
Read Story
BCAL Boosts Stake in Genetic Signatures to 18.46% to Expand Diagnostic Horizons
8:57am on Wednesday 26th of August, 2026 AEST
Key Points
BCAL acquires additional 8.25% stake in Genetic Signatures for $1.5 million
Total holding rises to 18.46% in complementary molecular diagnostics company
Strategic move to diversify into infectious disease testing alongside cancer diagnostics
BCAL maintains focus on commercialising breast and pancreatic cancer tests
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Bcal Diagnostics (ASX:BDX)
OPEN ARTICLE